Development of Mefenamic Acid-Soluplus® amorphous dispersions via hot melt extrusion and in silico prediction of oral absorption

The objective of this study was to increase the solubility of Mefenamic Acid (MA), a BCS class II drug by formulating amorphous solid dispersions via Hot-Melt Extrusion. The extrudates were prepared at different drug to polymer ratios and characterised by standard analytical techniques. Dissolution studies were performed in Phosphate buffer saline (PBS) pH 7.4 medium. Stability of the different ratios of MA: Soluplus (1:1, 1:4 and 4:1) was studied at room temperature for 12 months.

Computer simulation using GastroPlus™ was run to depict the gastrointestinal absorption of MA in humans. DSC thermograms and the diffractograms of the solid dispersions confirmed amorphous nature. Dissolution studies showed enhanced dissolution rate of MA from the solid dispersions. Stability studies indicated 1:4 (MA: Soluplus®) dispersion as the most stable dispersion. GastroPlus™ simulation using in vitro data showed improvement in the PK parameters of the solid dispersión in comparison with pure MA.

Download the full article as PDF here Development of Mefenamic Acid-Soluplus® amorphous dispersions via hot melt extrusion and in silico prediction of oral absorption

or read it here

Materials

Mefenamic acid was purchased from Yarrow Chem Products, Mumbai, India. Soluplus® (Mw = 118,000 g/mol, density = 1.08 g/cm3 ) was a gift from BASF. All other chemicals and reagents were of analytical grade and used in the study without further purification.

Estrella CHAVERO, Aleksandra KUROWSKA, Shaila A LEWIS, Development of Mefenamic Acid-Soluplus® amorphous dispersions via hot melt extrusion and in silico prediction of oral absorption, Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal – 576104, Karnataka, India, Acta Pharm. Sci. Vol 61:(1), 2023, DOI: 10.23893/1307-2080.APS